1 active not recruiting, 1 completed, 1 unknown. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow AriBio Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of AR1005 in Patients with Lewy Body Disease AR1005, Placebo, Rivastigmine 3 mg - Lewy Body Dementia | Phase 2 | Unknown | Yonsei University | 60 | 2024-01-01 | 2024-10-02 |
| Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) AR1001, Placebo - Alzheimer Disease | Phase 3 | Active not recruiting | AriBio Co., Ltd. | 1535 | 2022-12-23 | 2026-10-14 |
| Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease AR1001, Placebo - Mild to Moderate Alzheimer's Disease | Phase 2 | Completed | AriBio Co., Ltd. | 210 | 2019-04-01 | 2021-07-21 |
Alzheimer Disease (2) · Lewy Body Disease (1)
Appointments and Schedules (1) · Rivastigmine (1)
South Korea (2) · United States (2) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · United Kingdom (1)
James Rock (2) · Byoung Seok Ye, MD, PhD (1) · Sharon Sha, MD, MS (1)